CANCER

Scope & Guideline

Advancing the frontiers of cancer research.

Introduction

Welcome to the CANCER information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of CANCER, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0008-543x
PublisherWILEY
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1948 to 2024
AbbreviationCANCER-AM CANCER SOC / Cancer
Frequency24 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

The journal "CANCER" focuses on disseminating high-quality research that spans a wide array of topics in oncology. Its primary aim is to advance the understanding of cancer biology, treatment, and prevention, while promoting interdisciplinary approaches to tackle the complexities of cancer care. The journal emphasizes innovative methodologies and clinical applications, fostering collaboration among researchers, clinicians, and public health professionals.
  1. Cancer Biology and Genetics:
    Research that investigates the underlying biological mechanisms of cancer, including genetic mutations, epigenetics, and tumor microenvironment interactions.
  2. Clinical Trials and Therapeutics:
    Publications related to clinical trials evaluating new therapies, including immunotherapy, targeted therapies, and combination treatments, focusing on their efficacy and safety.
  3. Epidemiology and Prevention:
    Studies exploring cancer incidence, risk factors, and preventive measures, particularly in diverse populations and underserved communities.
  4. Patient-Centered Care and Survivorship:
    Research emphasizing the importance of quality of life, psychosocial factors, and survivorship issues for cancer patients, including financial toxicity and health disparities.
  5. Health Policy and Access to Care:
    Discussions on healthcare access, disparities in cancer treatment, and policy implications affecting cancer care delivery.
  6. Innovative Technologies in Cancer Treatment:
    Exploration of new technologies, including artificial intelligence and precision medicine, that enhance cancer diagnosis, treatment, and monitoring.
Recent publications in "CANCER" highlight several emerging themes that are gaining traction in the field of oncology. These trends reflect the journal's commitment to addressing contemporary challenges in cancer treatment and care, particularly in the context of evolving scientific knowledge and patient needs.
  1. Personalized and Precision Medicine:
    A growing emphasis on tailoring cancer treatment based on genetic, molecular, and patient-specific factors, leading to more effective and individualized therapies.
  2. Health Disparities and Equity in Cancer Care:
    Increased research focus on understanding and addressing disparities in cancer care and outcomes based on race, socioeconomic status, and geographic location.
  3. Integration of Technology in Cancer Care:
    The rise of digital health technologies, including telemedicine and mobile health apps, to enhance patient monitoring, treatment adherence, and communication in oncology.
  4. Palliative Care and Quality of Life:
    A significant uptick in studies examining the integration of palliative care early in the treatment process, focusing on improving quality of life and symptom management for patients.
  5. Immunotherapy Advances:
    Continued exploration of immunotherapeutic approaches, including combination therapies and novel agents, as a primary treatment modality for various cancers.
  6. Cancer Survivorship and Long-Term Effects:
    Research on the long-term impacts of cancer treatments on survivors, addressing both physical and psychosocial health outcomes.

Declining or Waning

While "CANCER" continues to evolve, certain research themes have seen a decline in focus over the recent years. These waning scopes may reflect shifting priorities within the oncology community or advancements in treatment options that have rendered previous research less relevant.
  1. Traditional Chemotherapy Studies:
    Research centered on standard chemotherapy regimens has decreased, likely due to the increasing emphasis on personalized medicine and targeted therapies that offer improved outcomes.
  2. Epidemiological Studies on Common Cancers:
    There is a noticeable reduction in publications focusing exclusively on common cancers (like breast and prostate cancer) without addressing disparities or novel treatment approaches.
  3. Basic Science without Clinical Relevance:
    Studies that focus solely on basic cancer biology without clear clinical implications or applications have become less prominent as the field shifts toward translational research.
  4. Longitudinal Studies without Intervention Focus:
    Longitudinal studies that do not propose or evaluate new interventions or treatment strategies are less frequently published, as there is a push for actionable research that impacts patient care.
  5. General Health Services Research:
    While still important, general studies on healthcare services are being overshadowed by more targeted research that addresses specific cancer types, therapies, and patient populations.

Similar Journals

Journal of Cancer

Innovative insights for a cancer-free future.
Publisher: IVYSPRING INT PUBLISSN: 1837-9664Frequency: 12 issues/year

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

LANCET ONCOLOGY

Pioneering insights in the fight against cancer.
Publisher: ELSEVIER SCIENCE INCISSN: 1470-2045Frequency: 12 issues/year

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Cancer Control

Fostering collaboration for a healthier tomorrow.
Publisher: SAGE PUBLICATIONS INCISSN: 1073-2748Frequency: 1 issue/year

Cancer Control is a prominent open-access journal published by SAGE Publications Inc, dedicated to advancing the field of oncology, hematology, and general medicine since its inception in 1995. With a focus on disseminating high-quality research, the journal contributes significantly to the knowledge base surrounding cancer prevention, treatment, and survivorship, making it a vital resource for researchers, healthcare professionals, and students alike. The journal currently holds a commendable position in the academic landscape, ranking in the Q2 category for both Hematology and Oncology, highlighting its impact and scholarly relevance. Available in an open-access format since 2018, Cancer Control ensures that critical findings are accessible to a broad audience, promoting collaboration and innovation in cancer-related research. Whether you're interested in the latest clinical trials, epidemiological studies, or public health initiatives, this journal serves as a key platform for sharing significant developments in cancer care and control.

Breast Cancer

Connecting global minds to combat breast cancer challenges.
Publisher: SPRINGER JAPAN KKISSN: 1340-6868Frequency: 6 issues/year

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Cancer Communications

Pioneering Discoveries in Cancer Communications
Publisher: WILEYISSN: Frequency: 12 issues/year

Cancer Communications, published by WILEY, is a leading open-access journal that has positioned itself at the forefront of cancer research and oncology since its inception in 2017. With an impressive HIndex reflective of its scholarly impact and recognized in the Q1 category for both Cancer Research and Oncology as of 2023, this journal consistently ranks in the top echelons of its field, specifically at Rank #16/404 and Rank #13/230 in their respective categories on Scopus. Cancer Communications aims to disseminate cutting-edge research findings, innovative methodologies, and significant advancements in cancer treatments, thereby fostering a deeper understanding of oncology among researchers, healthcare professionals, and students. The journal operates under an Open Access model since 2018, ensuring that vital research is accessible to a global audience, thus enhancing collaboration and knowledge sharing necessary to tackle one of the most pressing health challenges of our time. Located in Hoboken, NJ, United States, and with a strong commitment to scientific excellence, Cancer Communications remains an essential resource for anyone engaged in the fight against cancer.

CURRENT PROBLEMS IN CANCER

Advancing Oncology: Addressing Today’s Challenges in Cancer Research
Publisher: MOSBY-ELSEVIERISSN: 0147-0272Frequency: 6 issues/year

CURRENT PROBLEMS IN CANCER is an esteemed journal published by MOSBY-ELSEVIER, dedicated to advancing the field of oncology and cancer research. With an ISSN of 0147-0272 and an E-ISSN of 1535-6345, it has been a vital resource for over four decades, converging years of expertise from 1976 to 2024. The journal is recognized for its impactful contribution to the field, currently holding a Q3 ranking in Cancer Research and a Q2 ranking in Oncology, reflecting its importance in disseminating significant advancements and discussions in the field. It is ranked #164 out of 404 in Medicine _ Oncology and #131 out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research on Scopus, indicating its relevance and reach among academic circles. Although it does not offer open access, the journal remains a crucial platform for researchers and professionals seeking to explore contemporary issues in cancer treatment and management. With its commitment to quality and innovation, CURRENT PROBLEMS IN CANCER serves as an essential conduit for knowledge sharing and research development in oncology and cancer science.

BREAST

Empowering oncology with innovative insights.
Publisher: CHURCHILL LIVINGSTONEISSN: 0960-9776Frequency: 6 issues/year

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Oncology Research and Treatment

Elevating cancer research to new heights.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

CANCER SCIENCE

Empowering global access to vital cancer research findings.
Publisher: WILEYISSN: 1347-9032Frequency: 12 issues/year

Cancer Science, an esteemed journal published by Wiley, stands at the forefront of oncology research, boasting an impressive impact factor and a classification in the Q1 category for its contributions in Cancer Research, Medicine, and Oncology as of 2023. Since its inception in 2003 and transitioning to an Open Access model in 2014, the journal has facilitated global dissemination of critical research findings, ensuring that vital information remains accessible to researchers, clinicians, and students alike. With its comprehensive scope covering cutting-edge discoveries in cancer biochemistry, genetics, and molecular biology, Cancer Science is recognized for its rigorous peer-review process and significant contributions to advancing our understanding of cancer. The journal, located at 111 River St, Hoboken, NJ, is an essential resource for anyone dedicated to improving treatment outcomes and pushing the boundaries of cancer research.

INTERNATIONAL JOURNAL OF CANCER

Exploring the frontiers of cancer science and treatment.
Publisher: WILEYISSN: 0020-7136Frequency: 24 issues/year

INTERNATIONAL JOURNAL OF CANCER, published by Wiley, stands as a premier platform for the dissemination of cutting-edge research in the fields of cancer research and oncology. With an impressive impact factor reflecting its rigorous peer-review process and significant contribution to the scientific community, this journal is categorized in Q1 for both Cancer Research and Oncology as of 2023. It boasts notable rankings, being placed 38th among 404 journals in Medicine - Oncology and 32nd among 230 in Biochemistry, Genetics, and Molecular Biology - Cancer Research, positioning it within the 90th and 86th percentiles, respectively. Since its inception in 1966 and continuing to 2024, the journal has played a pivotal role in advancing our understanding of cancer biology, treatment modalities, and innovative therapeutic approaches. While it operates under a subscription model, the journal is committed to making valuable research accessible to a broader scientific audience. Researchers, professionals, and students alike will find the INTERNATIONAL JOURNAL OF CANCER an essential resource for staying abreast of the latest advancements in cancer science.